Thank you for your interest in the Rxight® Pharmacogenetics Program. Currently, the Rxight® Pharmacogenetics program is under review by the FDA as part of their pre-market submission program. During this time, a decision has been made not to offer Rxight® to the public.
We request your patience as we work together with the FDA and make Rxight® available again as soon as possible.
Here at the lab, we believe in the clinical support that pharmacogenetics can provide and will do everything we can to satisfy the FDA and return Rxight® to the pharmacists and physicians looking for help with their patients medication therapies.
If you would like to be contacted by Rxight® with updates, please contact us at email@example.com.